- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06909825
FPI-2265 (225AC-PSMA-I & T) a Olaparib u pacientů s metastatickou rakovinou prostaty rezistentní na kastraci (MCRPC)
Studie FPI-2265 (225AC-PSMA-I&T) a Olaparibu u účastníků s metastatickým karcinomem prostaty prostaty (MCRPC) u účastníků s metastatickým rakovinou prostaty (MCRPC) u účastníků s metastatickou rakovinou prostaty (MCRPC) s otevřeným znakem (MCRPC) u účastníků s metastatickou kastrací (MCRPC) u účastníků s metastatickou kastrací rakovinou prostaty (225AC-PSMA-I & T) a olaparibu u účastníků s metastatickým karcinomem prostaty (MCRPC) s metastatickým rakovinou prostaty (225AC-PSMA-I & T) a Olaparibu u metastatických rakoviny prostaty (MCRPC).
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I&T) in combination with Olaparib in participants with mCRPC. The study will be conducted in two parts, with Part A enrolling participants who have been previously treated with lutetium-177 (177Lu) vipivotide tetraxetan or other 177Lu-PSMA radioligand therapy (RLT) and Part B enrolling participants who have not been previously treated with lutetium-177 (177Lu) vipivotide tetraxetan or other 177Lu-PSMA radioligand therapy. For each part of the study, a Simon 2-stage design will be used to evaluate two dosing regimens. The purpose of this investigation is to determine the recommended FPI-2265 dose and regimen. Conclusions from this Phase 2 study will be based on safety, tolerability, and anti-tumor activity data. Participants with PSMA-positive mCRPC will be allocated to Arm 1 and Arm 2 in a singular, alternating fashion, until all Stage 1 participants are enrolled into each of the two regimens:
Arm 1: Will consist of up to six doses of FPI-2265 every six weeks at Dose A and olaparib twice a day on days 1 to 14 of each cycle.
Arm 2: Will consist of up to nine doses of FPI-2265 every four weeks at Dose B and olaparib twice a day on days 1 to 14 of each cycle Participants will be monitored and assessed for efficacy response, disease progression, and adverse events.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Macquarie Park, New South Wales, Austrálie, 2113
- Macquarie University Hospital
-
-
Queensland
-
Woolloongabba, Queensland, Austrálie, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Kurralta Park, South Australia, Austrálie, 5037
- Icon Cancer Centre Kurralta Park
-
-
Victoria
-
Melbourne, Victoria, Austrálie, 3000
- Peter MacCallum Cancer Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Adult male participants with mCRPC that is progressing at the time of study entry
-
ECOG performance status 0-1 and life expectancy of at least three months
-
Must have received at least one novel anti-androgen deprivation therapy
-
Participants with known BRCA mutations should have received approved therapies such as PARP inhibitors, per Investigator discretion.
-
All prior treatment-related AEs must have resolved to CTCAE Grade ≤1 (except alopecia).
-
Participants must have had prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L)
-
Positive PSMA PET/CT scans .
-
Participants must have adequate organ and bone marrow function:
- Hgb >/= 9g/dL
- Platelets >/= 100 x 10^9/L
- ANC </= 1.5 x 10^9/L
- CrCL >/= 50 mL/min
Exclusion Criteria:
- Previous treatment with any of the following within 6 months of first dose: Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation.
- Participants who received more than two (2) prior lines of cytotoxic chemotherapy for CRPC.
- Participants with known unresolved urinary tract obstruction.
- Transfusion- or growth factor-dependent participants.
- Participants with a history of CNS metastases are excluded, except those who have received therapy (and are neurologically stable, asymptomatic, and not receiving corticosteroids for the purposes of maintaining neurologic integrity.
- Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
- Participants with any liver metastases.
- Participants with skeletal metastases presenting as a superscan .
- Previous history of interstitial lung disease or non-infectious pneumonitis.
- Participants with a history or clinical and/or laboratory features suggestive of MDS/AML.
- Major surgery ≤28 days prior to the first dose of study treatment.
- Planning to conceive a pregnancy during the treatment and up to six months after the last treatment.
- Participants unable to swallow orally administered medications or with malabsorptive gastrointestinal disorders.
- Concomitant use of known strong or moderate CYP3A inhibitors or inducers
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Part A
Regimen 1: FPI-2265 (Dose A intravenously [IV] every six weeks) plus olaparib (twice daily [BID], on Days 1 to 14 of each cycle). Regimen 2: . FPI-2265 (Dose B intravenously [IV] every 4 weeks) plus olaparib (twice daily [BID], on Days 1 to 14 of each cycle) |
PSMA ligand radiolabeled with Ac225 Poly (ADP-ribose) polymerase (PARP) inhibitor |
|
Experimentální: Part B
Regimen 1: FPI-2265 (Dose A intravenously [IV] every six weeks) plus olaparib (g twice daily [BID], on Days 1 to 14 of each cycle). Regimen 2: . FPI-2265 (Dose B intravenously [IV] every 4 weeks) plus olaparib (twice daily [BID], on Days 1 to 14 of each cycle) |
PSMA ligand radiolabeled with Ac225 Poly (ADP-ribose) polymerase (PARP) inhibitor |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Evaluate anti-tumour activity of FPI-2265 administered in combination with olaparib
Časové okno: From first dose until approximately 12 weeks after the first administered dose of FPI-2265
|
The frequency and proportion of participants with PSA50 response will be summarized, where PSA50 is defined as ≥50% decline in PSA level from pre-treatment. |
From first dose until approximately 12 weeks after the first administered dose of FPI-2265
|
|
Evaluate the safety and tolerability of FPI-2265 administered in combination with olaparib
Časové okno: From first dose until end of long-term follow-up, 5 years from the last administered dose of FPI-2265
|
Safety will be assessed by percentage of patient with treatment emergent adverse events and serious adverse events; percentage of patients with SAEs during the first year of the long term follow up and the number of AESIs during the 5 year follow up period. Percentage of patients with interruption of FPI-2265; percentage of patients who discontinue treatment; number and grade for AEs related to study treatment. |
From first dose until end of long-term follow-up, 5 years from the last administered dose of FPI-2265
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Dipti Shoop, Fusion Pharmaceuticals Inc.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- FPI-2265-203
- CT-2024-CTN-00137-1 (Jiný identifikátor: TGA Clinical Trial Notification (CTN))
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .